Propanc Biopharma (PPCB) Capital Expenditures (2011 - 2025)

Propanc Biopharma (PPCB) posted quarterly Capital Expenditures of $2267.0 for Q4 2025, down 8.99% quarter-over-quarter from $2491.0 in Q3 2025.

Propanc Biopharma (PPCB) Capital Expenditures (2011 - 2025) Analysis & Trends

Propanc Biopharma (PPCB) has reported Capital Expenditures for 5 consecutive years, with $2267.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Capital Expenditures changed N/A year-over-year to $2267.0; the TTM figure through Dec 2025 stood at $5970.0 (changed N/A YoY), while the FY2019 annual figure was $2874.0, changed N/A from the prior year.
Capital Expenditures eased to $2267.0 in Q4 2025 per PPCB's latest filing, from $2491.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $2491.0 in Q3 2025 and bottomed at $2267.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	34.68 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	6.26 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	251.02 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-73.57 Mn
10	Propanc Biopharma	587,855.41	587,855.41	-	2,267.00

Download Data